Page 14 - PROPOSAL LATIP Zanamivir_Neat 2

be randomized to be administered orally (30 mg/kg) with either

nanoemulsion, microemulsion and control formulation, respectively. In
this instance, 3.0% w/w of captopril in olive oil, an emulsion formed

without the use of glycerol and sucrose ester surfactant will be use as a
control. Then, rats will be anesthetized with ketamine: xylazine; ratio of

2:1. Blood samples (0.25 ml) will be collected from the jugular vein using

heparinized syringes at predetermined time intervals of 0, 0.25, 0.5, 1.0,
1.5, 2.0, 3.0, 4.0, 5.0 and 6.0 h. Plasma samples will be treated with DA

prior to UPLC (Waters, USA) analysis.

4.0 REFERENCES

Akash S Ingale, Sandhya S Ahire, Sujeetkumar I Ahire, & Parag R. Patil. (2021).
Formulation and evaluation of fast dissolving tablets of captopril. GSC Biological
and Pharmaceutical Sciences, 17(2), 123–130.
https://doi.org/10.30574/gscbps.2021.17.2.0338
Al Jbour, N. D. (2022). Enhanced oral bioavailability through nanotechnology in Saudi
Arabia: A meta-analysis. Arabian Journal of Chemistry, 15(4), 103715.
https://doi.org/10.1016/j.arabjc.2022.103715
Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., & Ahmad, M. Z. (2021). Advances in Oral
Drug Delivery. Frontiers in Pharmacology, 12.
https://doi.org/10.3389/fphar.2021.618411
Aungst, B. J. (2012). Absorption Enhancers: Applications and Advances. The AAPS
Journal, 14(1), 10–18. https://doi.org/10.1208/s12248-011-9307-4
Buzea, C., Pacheco, I. I., & Robbie, K. (2007). Nanomaterials and nanoparticles: Sources
and toxicity. Biointerphases, 2(4), MR17–MR71. https://doi.org/10.1116/1.2815690
Caco-2 Permeability Assay - IONTOX. (2020, March 27). IONTOX.
https://www.iontox.com/caco-2-permeability-assay/
Cao, Q., Wu, H., Zhu, L., Wu, D., Zhu, Y., Zhu, Z., & Cui, J. (2011). Preparation and
evaluation of zanamivir-loaded solid lipid nanoparticles. Journal of Controlled
Release, 152, e2–e4. https://doi.org/10.1016/j.jconrel.2011.08.085
Cass, L. M. R., Efthymiopoulos, C., & Bye, A. (1999). Pharmacokinetics of Zanamivir
After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers.
Clinical Pharmacokinetics, 36(Supplement 1), 1–11.
https://doi.org/10.2165/00003088-199936001-00001
Cheer, S. M., & Wagstaff, A. J. (2002). Zanamivir. Drugs, 62(1), 71–106.